Can future reirradiation justify upfront proton therapy? An extension of model-based proton therapy selection beyond primary-course NTCP benefit

Objective: Current model-based proton therapy selection values normal tissue sparing only through its immediate reduction in normal tissue complication probability (NTCP). If reirradiation later adds further dose to the normal tissue, sparing achieved during primary treatment may become more clinica